The estimated Net Worth of Richard Mulligan is at least $3.31 Million dollars as of 29 May 2013. Richard Mulligan owns over 3,000 units of Biogen Inc stock worth over $999,432 and over the last 15 years he sold BIIB stock worth over $1,912,484. In addition, he makes $401,393 as Independent Director at Biogen Inc.
Richard has made over 4 trades of the Biogen Inc stock since 2013, according to the Form 4 filled with the SEC. Most recently he exercised 3,000 units of BIIB stock worth $160,290 on 29 May 2013.
The largest trade he's ever made was exercising 37,975 units of Biogen Inc stock on 28 May 2013 worth over $2,029,004. On average, Richard trades about 2,357 units every 4 days since 2009. As of 29 May 2013 he still owns at least 5,020 units of Biogen Inc stock.
You can see the complete history of Richard Mulligan stock trades at the bottom of the page.
Dr. Richard C. Mulligan, Ph.D. is an Independent Director of Biogen Inc. Dr. Mulligan is currently the Mallinckrodt Professor of Genetics, Emeritus, at Harvard Medical School, after serving as the Mallinckrodt Professor of Genetics and Director of the Harvard Gene Therapy Initiative from 1996 to 2013. He also currently serves as Executive Vice Chairman of the Board of Sana Biotechnology, a private biotechnology company. From March 2017 to October 2018 Dr. Mulligan served as a Portfolio Manager at Icahn Capital LP. Prior to that, Dr. Mulligan was a founding partner of Sarissa Capital Management LP, a registered investment advisor, from 2013 to 2016. Prior to Harvard, Dr. Mulligan was a Professor of Molecular Biology at the Massachusetts Institute of Technology, a member of the Whitehead Institute for Biomedical Research and the Chief Scientific Officer of Somatix Therapy Corporation, a drug discovery and development company that he founded. Dr. Mulligan was named a MacArthur Foundation Fellow in 1981.
As the Independent Director of Biogen Inc, the total compensation of Richard Mulligan at Biogen Inc is $401,393. There are 17 executives at Biogen Inc getting paid more, with Michel Vounatsos having the highest compensation of $18,159,900.
Richard Mulligan is 63, he's been the Independent Director of Biogen Inc since 2009. There are 7 older and 16 younger executives at Biogen Inc. The oldest executive at Biogen Inc is Stelios Papadopoulos, 72, who is the Independent Chairman of the Board.
Richard's mailing address filed with the SEC is 400 SOMERSET CORPORATE BLVD., , BRIDGEWATER, NJ, 08807.
Over the last 21 years, insiders at Biogen Inc have traded over $166,883,156 worth of Biogen Inc stock and bought 665,319 units worth $183,001,783 . The most active insiders traders include Adam Koppel, Alexander J Denner und Stelios Papadopoulos. On average, Biogen Inc executives and independent directors trade stock every 10 days with the average trade being worth of $2,343,090. The most recent stock trade was executed by Priya Singhal on 30 August 2024, trading 1,668 units of BIIB stock currently worth $332,082.
through cutting-edge science and medicine, biogen discovers, develops and delivers innovative therapies worldwide for people living with serious neurological and neurodegenerative diseases. founded in 1978, biogen is a pioneer in biotechnology and today the company has the leading portfolio of medicines to treat multiple sclerosis, has introduced the first and only approved treatment for spinal muscular atrophy, and is at the forefront of neurology research for conditions including alzheimer’s disease, parkinson’s disease and amyotrophic lateral sclerosis. biogen also manufactures and commercializes biosimilars of advanced biologics. with approximately 7000 people worldwide, we are truly a global organization, headquartered in cambridge, massachusetts, which is also home to our research operations. our international headquarters are based in zug, switzerland and we have world-class manufacturing facilities in north carolina and denmark. we offer therapies globally through direct affili
Biogen Inc executives and other stock owners filed with the SEC include: